- Home
- BIIB vs FTAI Comparison
BIIB vs FTAI Comparison
Compare BIIB & FTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FTAI
- Stock Information
- Founded
- BIIB 1978
- FTAI 2011
- Country
- BIIB United States
- FTAI United States
- Employees
- BIIB N/A
- FTAI N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FTAI Misc Corporate Leasing Services
- Sector
- BIIB Health Care
- FTAI Industrials
- Exchange
- BIIB Nasdaq
- FTAI Nasdaq
- Market Cap
- BIIB 18.7B
- FTAI 16.9B
- IPO Year
- BIIB 1991
- FTAI 2015
- Fundamental
- Price
- BIIB $157.08
- FTAI $161.69
- Analyst Decision
- BIIB Buy
- FTAI Strong Buy
- Analyst Count
- BIIB 24
- FTAI 10
- Target Price
- BIIB $174.62
- FTAI $199.00
- AVG Volume (30 Days)
- BIIB 1.6M
- FTAI 1.4M
- Earning Date
- BIIB 10-30-2025
- FTAI 10-27-2025
- Dividend Yield
- BIIB N/A
- FTAI 0.86%
- EPS Growth
- BIIB N/A
- FTAI N/A
- EPS
- BIIB 10.97
- FTAI 4.36
- Revenue
- BIIB $10,065,900,000.00
- FTAI $2,344,200,000.00
- Revenue This Year
- BIIB $2.97
- FTAI $50.04
- Revenue Next Year
- BIIB N/A
- FTAI $23.67
- P/E Ratio
- BIIB $14.28
- FTAI $37.20
- Revenue Growth
- BIIB 4.77
- FTAI 51.35
- 52 Week Low
- BIIB $110.04
- FTAI $75.06
- 52 Week High
- BIIB $179.20
- FTAI $194.36
- Technical
- Relative Strength Index (RSI)
- BIIB 64.92
- FTAI 43.81
- Support Level
- BIIB $148.90
- FTAI $152.44
- Resistance Level
- BIIB $155.33
- FTAI $187.70
- Average True Range (ATR)
- BIIB 4.79
- FTAI 9.84
- MACD
- BIIB 0.47
- FTAI -2.38
- Stochastic Oscillator
- BIIB 96.41
- FTAI 22.08
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.